SFM
Sphera Funds Management Portfolio holdings
AUM
$382M
This Quarter Return
+10.94%
1 Year Return
+0.41%
3 Year Return
+99.29%
5 Year Return
+177.09%
10 Year Return
+575.73%
AUM
$382M
AUM Growth
+$382M
(-5.7%)
Cap. Flow
-$40.1M
Cap. Flow
% of AUM
-10.48%
Top 10 Holdings %
Top 10 Hldgs %
34.79%
Holding
131
New
16
Increased
23
Reduced
53
Closed
27
Top Buys
| 1 |
Tower Semiconductor
TSEM
|
$8.81M |
| 2 |
Biogen
BIIB
|
$7.54M |
| 3 |
Forte Biosciences
FBRX
|
$6.4M |
| 4 |
Cytokinetics
CYTK
|
$6.01M |
| 5 |
Cidara Therapeutics
CDTX
|
$5.89M |
Top Sells
| 1 |
BridgeBio Pharma
BBIO
|
$12.1M |
| 2 |
Ultragenyx Pharmaceutical
RARE
|
$6.08M |
| 3 |
Nice
NICE
|
$5.13M |
| 4 |
Merus
MRUS
|
$4.48M |
| 5 |
Sanofi
SNY
|
$4.11M |
Sector Composition
| 1 | Healthcare | 73.22% |
| 2 | Technology | 19.05% |
| 3 | Consumer Discretionary | 1.86% |
| 4 | Utilities | 1.71% |
| 5 | Communication Services | 1.65% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
GSK
GSK
$79.3B
| $4.68M | 1.1% |
122,000
-8,000
| -6% | -$307K |
|
27
Praxis Precision Medicines
PRAX
$980M
| $4.62M | 1.08% |
109,757
-30,903
| -22% | -$1.3M |
|
28
Novartis
NVS
$248B
| $4.48M | 1.05% |
37,000
-13,000
| -26% | -$1.57M |
|
29
Trevi Therapeutics
TRVI
$871M
| $4.38M | 1.03% |
+799,957
| New | +$4.38M |
|
|
MAZE
30
Maze Therapeutics, Inc. Common Stock
MAZE
$666M
| $4.37M | 1.03% |
356,453
+899
| +0.3% | +$11K |
|
31
Annexon
ANNX
$225M
| $4.23M | 0.99% |
1,764,387
| – | – |
|
32
Immunovant
IMVT
$2.91B
| $4.11M | 0.96% |
256,743
+62,105
| +32% | +$994K |
|
33
Oric Pharmaceuticals
ORIC
$1.03B
| $4.01M | 0.94% |
394,693
+159,859
| +68% | +$1.62M |
|
34
Merck
MRK
$210B
| $3.85M | 0.9% |
48,600
-11,000
| -18% | -$871K |
|
35
Acadia Pharmaceuticals
ACAD
$4.34B
| $3.77M | 0.89% |
+174,900
| New | +$3.77M |
|
|
36
BridgeBio Pharma
BBIO
$9.91B
| $3.76M | 0.88% |
87,108
-279,500
| -76% | -$12.1M |
|
|
37
Ultragenyx Pharmaceutical
RARE
$3.04B
| $3.64M | 0.85% |
100,085
-167,300
| -63% | -$6.08M |
|
38
Avidity Biosciences
RNA
$6.12B
| $3.58M | 0.84% |
126,000
+20,000
| +19% | +$568K |
|
|
ACOG
39
Alpha Cognition Inc. Common Stock
ACOG
$132M
| $3.51M | 0.82% |
376,649
-220,343
| -37% | -$2.06M |
|
40
Rezolute
RZLT
$630M
| $3.35M | 0.79% |
751,447
-330,000
| -31% | -$1.47M |
|
|
CYBN
41
Cybin
CYBN
$142M
| $3.34M | 0.78% |
398,309
-128,913
| -24% | -$1.08M |
|
42
Applied Materials
AMAT
$124B
| $3.3M | 0.77% |
18,000
| – | – |
|
43
Arrowhead Research
ARWR
$3.84B
| $3.21M | 0.75% |
202,996
-74,554
| -27% | -$1.18M |
|
44
Immatics
IMTX
$662M
| $3.14M | 0.74% |
583,105
-338,006
| -37% | -$1.82M |
|
45
Savara
SVRA
$591M
| $2.99M | 0.7% |
1,310,233
+26,082
| +2% | +$59.5K |
|
46
Uber
UBER
$194B
| $2.8M | 0.66% |
30,000
| – | – |
|
47
Sarepta Therapeutics
SRPT
$1.98B
| $2.72M | 0.64% |
159,323
+1,392
| +0.9% | +$23.8K |
|
48
Camtek
CAMT
$3.51B
| $2.7M | 0.63% |
31,976
+8,890
| +39% | +$752K |
|
49
Elbit Systems
ESLT
$22.2B
| $2.7M | 0.63% |
+6,000
| New | +$2.7M |
|
50
Palo Alto Networks
PANW
$128B
| $2.68M | 0.63% |
+13,114
| New | +$2.68M |
|